RESUMEN
The current seventh pandemic of cholera, caused by serogroup O1, El Tor biotype, has now involved almost the entire developing world. The ongoing dynamic epidemiology of cholera, involving evolution of new strains, prolonged and more frequent epidemics, increased antimicrobial resistance, and awareness of the role of climate change upon the global burden has returned cholera to the forefront of global public health discussions. Improved water and sanitation should continue to be the mainstays of cholera-prevention efforts, but major improvements are a far-off goal for much of the cholera-affected developing world. The advent of safe and effective, new-generation oral vaccines against cholera has created renewed interest in the use of vaccines as a tool to control cholera.
Asunto(s)
Vacunas contra el Cólera/administración & dosificación , Vacunas contra el Cólera/inmunología , Cólera/epidemiología , Cólera/prevención & control , Pandemias/prevención & control , Administración Oral , Cólera/inmunología , Control de Enfermedades Transmisibles/métodos , Países en Desarrollo , HumanosRESUMEN
Dengue infection is endemic among children in Cambodia. Few studies have described the clinical characteristics, diagnoses and the socioeconomic impact of hospitalized dengue cases. As part of a multicountry prospective dengue study, we analysed interviews and record reviews of 123 consecutive cases of children hospitalized with confirmed dengue in a major public provincial hospital. About 80% of cases evidenced plasma leak. On average, a hospitalized dengue case lasted 6.3 days, with 3.3 days of inpatient care, and cost US$116 (Singapore dollar 48). The majority (88%) of these cases’ households reported a substantial adverse economic impact, perhaps explained by their inability to afford medical care (39%), or on account of loss of five or more days of income (91%), need to borrow money beyond family or friends (39%), being compelled to sell or sale of property (53%) to pay for treatment. Hospitalized dengue has major clinical and socioeconomic consequences in Cambodia.
Asunto(s)
Dengue , Cambodia , Factores Socioeconómicos , Hospitalización , Servicios de SaludRESUMEN
Despite the growing worldwide burden of dengue fever, the global economic impact of dengue illness is poorly documented. Using a common protocol, we present the first multicountry estimates of the direct and indirect costs of dengue cases in eight American and Asian countries. We conducted prospective studies of the cost of dengue in five countries in the Americas (Brazil, El Salvador, Guatemala, Panama, and Venezuela) and three countries in Asia (Cambodia, Malaysia, and Thailand). All studies followed the same core protocol with interviews and medical record reviews. The study populations were patients treated in ambulatory and hospital settings with a clinical diagnosis of dengue. Most studies were performed in 2005. Costs are in 2005 international dollars (I$). We studied 1,695 patients (48% pediatric and 52% adult); none died. The average illness lasted 11.9 days for ambulatory patients and 11.0 days for hospitalized patients. Among hospitalized patients, students lost 5.6 days of school, whereas those working lost 9.9 work days per average dengue episode. Overall mean costs were I$514 and I$1,394 for an ambulatory and hospitalized case, respectively. With an annual average of 574,000 cases reported, the aggregate annual economic cost of dengue for the eight study countries is at least I$587 million. Preliminary adjustment for under-reporting could raise this total to $1.8 billion, and incorporating costs of dengue surveillance and vector control would raise the amount further. Dengue imposes substantial costs on both the health sector and the overall economy.
Asunto(s)
Dengue/economía , Dengue/epidemiología , Costos de la Atención en Salud/estadística & datos numéricos , Adolescente , Adulto , Asia Sudoriental/epidemiología , América Central/epidemiología , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Estudios Prospectivos , América del Sur/epidemiología , Adulto JovenRESUMEN
In 2005, Panama experienced the largest dengue epidemic since 1993. We conducted both a prospective clinical and a national economic study. The full cost analysis measured costs of dengue cases and of dengue control efforts in the entire country. Costs are in 2005 US$. Ambulatory patients were 130 of the 136 participants, with 82% adults (18+) and 62% women. Duration of fever and illness averaged 6.1 (standard deviation [SD], 5.3) and 21.2 (SD 13.5) days, respectively. Loss in quality of life averaged 67% (SD 21) during the worst days of illness. An average ambulatory and hospitalized case cost $332 and $1,065, respectively. Although 5,489 cases were officially reported, the Ministry of Health (MOH) estimated 32,900 actual cases, implying a total cost of $11.8 million. Additionally, estimated government spending on dengue control efforts was $5 million. This dengue epidemic had a major disease impact and an economic cost of $16.9 million ($5.22 per capita).
Asunto(s)
Costo de Enfermedad , Dengue/economía , Dengue/epidemiología , Brotes de Enfermedades/economía , Costos de la Atención en Salud/estadística & datos numéricos , Adulto , Atención Ambulatoria/economía , Niño , Dengue/mortalidad , Femenino , Hospitalización/economía , Humanos , Masculino , Panamá/epidemiología , Estudios ProspectivosRESUMEN
Although the disease burden of dengue is increasing, the impact on the quality of life (QoL) has not been investigated. A study to determine the QoL of confirmed dengue patients using the EuroQol visual thermometer scale was carried out at the University Malaya Medical Center. Of the 207 participants, 40% were ambulatory and 60% were hospitalized. Of eight health domains, 6.2 and 5.0 domains were affected in the hospitalized and ambulatory cohorts, respectively (P < 0.001), with cognition and interpersonal activities affected most. All patients experienced a drastic decrease in their QoL from the onset of symptoms. The QoL deteriorated to the lowest point (40% of healthy status) between the third and seventh days of illness. The duration of impaired QoL (9 days for ambulatory or 13 days for hospitalized patients) was longer than the duration of fever (5 and 7 days, respectively). Symptomatic dengue has major effects on patients' health.